400,000 Patients Switched to a Pill in Ten Weeks. Your Injectable Is Next.

The Pill That Was Not Supposed to Exist

On March 18, 2026, the FDA approved ICOTYDE (icotrokinra), a once daily oral peptide that precisely antagonizes the interleukin 23 receptor, for moderate to severe plaque psoriasis in adults and adolescents 12 years and older. Johnson & Johnson and Protagonist Therapeutics built this molecule over 13 years. The approval triggers a $50 million milestone payment to Protagonist, with up to $580 million in additional milestones and 6% to 10% tiered royalties on global net sales.

In the ICONIC LEAD trial, 50% of adults on icotrokinra achieved PASI 90 (90% skin clearance) at week 16, compared to 4% on placebo. Complete clearance, PASI 100, reached 27% versus less than 1% on placebo. At week 52, among responders who continued treatment, 84% maintained PASI 90 and 89% maintained PASI 75. In adolescents, 86% achieved PASI 90 at one year.

In the ICONIC ADVANCE head to head studies against deucravacitinib (Sotyktu), icotrokinra outperformed across every endpoint, with lower adverse event rates: 57% versus 65% through 24 weeks. A network meta analysis found that icotrokinra achieved rates of completely clear skin comparable to injectable IL 23 inhibitors, biologics that cost tens of thousands of dollars per year and require refrigeration, clinic visits, or self injection.

Johnson & Johnson projects peak sales exceeding $5 billion. Jefferies sees $7.5 billion in peak U.S. sales, with global potential reaching $10 billion. Truist Securities estimates a $5 to $10 billion total market opportunity. And ICOTYDE is already in Phase 3 for psoriatic arthritis, ulcerative colitis, and Crohn's disease. If those indications succeed, the oral IL 23 franchise becomes one of the largest in pharmaceutical history.

Peptides are normally destroyed in the gut, cannot cross intestinal membranes, and fail to survive first pass metabolism. ICOTYDE exists because Protagonist solved a formulation problem that the industry assumed was intractable.

How Protagonist Cracked Oral Peptide Delivery

The science behind ICOTYDE begins in the laboratory of Mark Smythe in Australia, where Protagonist developed its constrained peptide engineering platform. The core innovation is disulfide cyclization combined with peptidomimetic modifications: rigidifying peptide structures by removing exposed N and C termini, the sites most vulnerable to enzymatic cleavage. This reduces intermolecular hydrogen bond formation, decreases hydrophilicity, and produces peptides stable enough to survive the gastrointestinal tract.

Central to the platform is Vectrix, a suite of molecular design tools and large virtual libraries of conformationally constrained scaffolds. Vectrix enables computational matching of functional and structural components against selected targets, followed by phage display optimization and oral stability assays that simulate the chemical and biological barriers peptides face during oral drug absorption. The approach is iterative: design computationally, test experimentally, refine, repeat, for over a decade.

The Vectrix platform is a systematic method for discovering constrained peptides that resist proteolytic degradation while retaining binding potency. That methodology can be pointed at any peptide target where injectable biologics currently dominate.

A network meta analysis found icotrokinra achieved rates of completely clear skin comparable to injectable IL 23 inhibitors and superior to other advanced oral treatments.

The Lancet, ICONIC ADVANCE data

The 13 year timeline from discovery to approval tells you something important about the difficulty of this work. Oral peptide delivery does not scale with compute. It is an experimental science problem that requires physical chemistry, GI physiology, manufacturing engineering, and clinical validation at every stage. The companies that win in oral biologics will be the ones that compress the experimental cycle without skipping it.

The Oral GLP 1 Arms Race

While ICOTYDE broke new ground in autoimmune disease, the oral GLP 1 market for obesity and diabetes is where the largest commercial stakes lie. Three molecules are defining the competitive field, each with a distinct formulation strategy.

Wegovy pill (oral semaglutide 25 mg) received FDA approval on December 22, 2025. Novo Nordisk acquired Emisphere Technologies for $1.8 billion to secure the SNAC permeation enhancer technology that makes oral semaglutide possible. In the OASIS 4 trial, the pill achieved 16.6% mean weight loss at 64 weeks, with one third of adherent participants losing at least 20% of their body weight. Indirect comparisons with injectable semaglutide showed comparable outcomes across weight reduction, cardiometabolic improvements, and quality of life. The 30 minute fasting requirement after consumption remains a practical constraint, but 400,000 Americans in ten weeks suggests patients are willing to live with it.

Aleniglipron, from Structure Therapeutics, reported Phase 2 data on March 16, 2026, that may be the most interesting dataset in the oral GLP 1 race. The ACCESS II trial showed 16.3% placebo adjusted weight loss at 44 weeks on the 180 mg dose, equivalent to 39 pounds. The 240 mg dose reached 16.0%. The critical detail: no evidence of a weight loss plateau. Open label extension data showed continued weight loss of up to 16.2% at 56 weeks with the 120 mg dose. Adverse event related discontinuations dropped to 2.0 to 3.4% with an optimized starting dose. Structure plans an FDA end of Phase 2 meeting in Q2 2026 and Phase 3 initiation in the second half of this year. Analysts have flagged Structure as a potential acquisition target on the strength of these results.

Orforglipron, Eli Lilly's oral GLP 1 receptor agonist, is structurally distinct: a small molecule, non peptide compound. This means no fasting requirements, no water restrictions, no time of day constraints. In the ATTAIN 1 Phase 3 trial of 3,127 adults, the 36 mg dose produced 12.4% mean weight loss at 72 weeks. Nearly 60% of participants on the highest dose lost at least 10% body weight, and 39.6% lost at least 15%. Orforglipron received one of the FDA's National Priority Review Vouchers. The PDUFA date was pushed to April 10, 2026, and Lilly has been stockpiling pre launch inventory.

The ATTAIN MAINTAIN study adds another dimension. Participants who switched from injectable semaglutide to oral orforglipron maintained their weight loss, with an average difference of just 0.9 kg. Those switching from tirzepatide maintained weight with a 5.0 kg difference. This switch maintenance data matters enormously for personalized medicine: it means oral formulations can serve as long term continuations of injectable therapy, not inferior alternatives.

Analyst projections for competitive launches stack up through the end of the decade: Amgen and Altimmune in 2027, Pfizer, Roche, Viking, and Structure in 2028, Roche, Viking, AstraZeneca, and Zealand in 2029. The oral GLP 1 market has more than a dozen companies in active development.

Getting a Biologic Past the Gut

The clinical results above matter precisely because oral biologic delivery has been considered nearly impossible for decades. The gastrointestinal tract evolved to destroy large, complex molecules. Delivering biopharmaceuticals through it requires defeating three barriers simultaneously.

Enzymatic degradation begins within minutes. Pepsin activates at low gastric pH and starts cleaving peptide bonds in the stomach. In the small intestine, pancreatic proteases, including trypsin, chymotrypsin, elastase, and carboxypeptidases, continue the assault. An unprotected peptide has a half life measured in minutes, not hours.

Low membrane permeability blocks what survives digestion. Large, hydrophilic peptide molecules cannot passively diffuse across the lipid bilayer of intestinal epithelial cells. Tight junctions between enterocytes restrict paracellular transport. Oral bioavailability for unformulated peptides is typically below 1 to 2%.

First pass metabolism claims what crosses the intestinal wall. Hepatic metabolism further reduces systemic exposure before the drug reaches its target. For Rybelsus, oral semaglutide bioavailability is approximately 1%, compared to over 50% for the subcutaneous injection. The manufacturing implication: you need dramatically more active pharmaceutical ingredient per oral dose, at dramatically higher cost.

The formulation strategies that overcome these barriers are among the most complex in current pharmaceutical science.

• SNAC (sodium salcaprozate): The permeation enhancer behind Rybelsus and Wegovy pill. Creates a local pH buffer to protect semaglutide from pepsin, promotes peptide monomerization by changing solution polarity, and fluidizes gastric cell membranes to increase permeability. Uniquely, drug absorption occurs in the stomach rather than the small intestine.
• Sodium caprate (C10): A medium chain fatty acid that transiently opens tight junctions between intestinal epithelial cells, enabling paracellular transport. Operates in the small intestine and requires enteric coating to prevent premature release.
• Constrained peptide engineering: The Protagonist approach. Disulfide cyclization and peptidomimetic modifications remove enzymatic vulnerability while maintaining target binding. Used in ICOTYDE.
• Nanoparticle encapsulation: Polymeric nanoparticles, liposomes, solid lipid nanoparticles, and lipid polymer hybrid systems prevent degradation by low pH and proteases. Approximately 40% of oral biologic formulations now incorporate nanocarrier systems.
• Protease inhibitor co formulation: Aprotinin and Bowman Birk inhibitor incorporated into microspheres and emulsion systems to shield oral insulin and calcitonin from enzymatic breakdown. Safety concerns around digestive function remain a limiting factor.
• Mucoadhesive systems: Materials that interact with the intestinal mucus layer to increase residence time at the absorption site, concentrating the biologic where it needs to cross.
• Cell penetrating peptides (CPPs): Short peptide sequences of 4 to 30 amino acids that facilitate transepithelial transport of biological cargo when encapsulated in protective carriers.
• Intestinal patch technology: Targeted drug delivery systems that adhere directly to the intestinal wall, creating a concentrated microenvironment for drug absorption while shielding the payload from luminal degradation.

Enteric coating technology remains foundational to oral biologic formulation. By preventing payload release in the stomach and targeting the small intestine, enteric coated modified release tablets ensure co release of permeation enhancer and macromolecule at the absorption site in high local concentrations. In 2025, researchers introduced an engineered synthetic intrinsically disordered protein (SynIDP) that assembles into an enteric coating, combining protein engineering with formulation science in a way that would have been unimaginable five years ago.

Each of these approaches involves its own excipient requirements, stability challenges, manufacturing constraints, and regulatory considerations. The formulation scientist working on oral biologics is not choosing one technology. They are orchestrating combinations of them.

Beyond Peptides: The Expanding Oral Pipeline

ICOTYDE and the oral GLP 1s are the first wave, but the pipeline extends into territories that will test drug delivery systems even further.

Oral insulin remains the field's defining unsolved problem. Oramed Pharmaceuticals is the most advanced developer, but their Phase 3 trial for ORMD 0801 did not meet its primary endpoint for HbA1c reduction. Subpopulations defined by BMI, baseline HbA1c, and age showed meaningful responses, and Oramed initiated a 60 patient U.S. trial in October 2025 targeting these responsive subgroups. In January 2026, Oramed announced agreements to transfer its POD technology to Lifeward Ltd. Oramed is not near imminent FDA approval. The 60 patient trial is designed to generate evidence, not serve as a pivotal submission. Insulin's molecular size (~5.8 kDa) and conformational sensitivity make oral delivery exceptionally difficult. Decades of effort have not cracked it.

Oral TNF inhibitors represent one of the largest conversion opportunities. Sanofi's SAR441566, an oral TNFR1 inhibitor, completed a Phase 1 proof of mechanism trial for psoriasis and is recruiting for Phase 2 in rheumatoid arthritis. But Sanofi's other candidate, balinatunfib, was statistically no better than placebo as monotherapy in a 221 patient Phase 2 psoriasis trial, a significant setback. Combination approaches are still being investigated for RA, Crohn's, and ulcerative colitis. TNF inhibitors are the largest biologic drug class. An effective oral TNF would reshape a multibillion dollar market.

Oral antibodies remain largely preclinical. Antibodies are approximately 150 kDa, far too large for conventional permeation enhancer strategies. Research centers on gastric auto injector devices that deliver biologics directly through the stomach wall and digestible antibody formulations using nanoparticles. No oral monoclonal antibody is in late stage clinical development as of March 2026.

Oral mRNA delivery is in the research phase, building on the lipid nanoparticle technology that proved effective for injectable COVID 19 vaccines. Recent advances include metal ion mediated mRNA enrichment using manganese ions to achieve nearly 2x mRNA loading capacity in LNPs, and a biodegradable ionizable lipid achieving 3.5 fold higher dendritic cell transfection than SM 102. Mouse studies showed an mRNA influenza vaccine could generate equivalent immune response at approximately 1/100th the dose using new LNP formulations. Most mucosal mRNA research currently targets nasal, vaginal, and rectal routes rather than oral administration.

Oral vaccines are further along. Vaxart's tablet based platform has an oral norovirus vaccine in Phase 1, an oral COVID 19 vaccine in Phase 2b with ~5,400 participants enrolled (Dynavax licensed the program for $25 million upfront plus $5 million in equity), and an oral avian influenza vaccine that achieved 100% protection against death in ferret challenge models.

The therapeutic areas moving toward oral biologics include new indications for S1P inhibitors and JAK inhibitors, more selective TYK2 inhibitors, oral therapies targeting IL 17, integrin, and TNF pathways, and novel mechanism targets including RIPK1, NLRX1, miR 124, BTK, and IRAK4.

Where Drug Delivery Technologies Converge

The oral biologics revolution builds on a set of drug delivery systems that are advancing in parallel and feeding into each other.

Antibody drug conjugates (ADCs) are one of the fastest growing segments in biopharmaceuticals, valued at $15.29 billion in 2025 and projected to reach $32.66 billion by 2035. H1 2025 global ADC sales hit an estimated $8 billion, with full year sales expected to exceed $16 billion. The technology is advancing rapidly: enzyme cleavable linkers ensure tumor microenvironment specific activation, pH sensitive linkers reduce premature systemic release, and site specific conjugation improves the therapeutic index. New drug conjugate platforms extend beyond traditional ADCs into bispecific ADCs targeting two antigens, probody drug conjugates activated by tumor specific proteases, immunostimulating ADCs combining targeted delivery with immune activation, degrader antibody conjugates using targeted protein degradation, and antibody peptide conjugates like Amgen's MariTide for obesity. The linker chemistry, payload engineering, and targeted release mechanisms developed for ADCs directly inform how oral biologic formulations control where and when a drug becomes active.

Liposomal drug delivery is a $6.34 billion market in 2026, projected to reach $13.54 billion by 2035 at 8.7% CAGR. PEGylated liposomal formulations remain the clinical standard, with expanding trials in multiple myeloma, breast cancer, and gliomas. The next frontier is stimulus responsive liposomes that release payloads in response to pH changes, temperature, or enzyme activity. That same responsive release logic is being adapted for oral biologic formulations, where pH triggered release in the intestinal environment protects peptide payloads through the stomach.

Modified release tablet technology is changing because of 3D printing that enables personalized medicines with customizable release kinetics, AI predictive modeling for optimizing drug release profiles, novel excipients including nanoparticles and liposomes integrated into oral solid dosage forms, real time Process Analytical Technologies (PAT) for quality by design manufacturing, model informed drug development (MIDD) accelerating formulation design, and continuous manufacturing replacing traditional batch processes. Every one of these advances applies directly to oral biologic formulations.

The convergence matters because the formulation scientist working on an oral biologic draws on knowledge from ADC linker chemistry, liposomal encapsulation, modified release tablet engineering, and nanoparticle design simultaneously. These are different expressions of the same underlying discipline: controlling how, where, and when a drug becomes available in the body.

Formulation Science Is the Bottleneck

The oral biologics revolution exposes a fundamental gap in the pharmaceutical workforce. Most formulation scientists were trained on small molecules, understanding crystallography, solid state chemistry, and conventional excipient compatibility. Oral peptide and biologic formulation demands an entirely different knowledge base: peptide stability and degradation pathways (deamination, isomerization, oxidation, aggregation), permeation enhancer chemistry and mechanisms of action, nanoparticle engineering and characterization, bioassay development for potency testing, computational modeling of peptide excipient interactions, and GI physiology at a molecular level.

The gap extends to digital capabilities. Formulation scientists are experts in physical chemistry, pharmacokinetics, and regulatory science. They are not, by training, fluent in data modeling, Python, or neural network architecture. The oral biologics field requires both skill sets simultaneously.

With three excipients at five concentrations and five process parameters at three settings, the total design space encompasses 3,645,000 possible formulations.

ScienceDirect, ML Guided Formulation Optimization (2026)

Manufacturing compounds the challenge. Scaling oral peptide production means confronting synthesis complexity (longer peptides require more coupling steps, increasing error probability and decreasing yields), moisture sensitivity requiring controlled humidity environments, susceptibility to deamination and isomerization during processing, dramatically higher API requirements due to low oral bioavailability, and batch consistency requirements that demand deep understanding of peptide structure and physicochemical properties. Quality control for oral biologics encompasses dissolution testing adapted for peptide specific release profiles, stability studies addressing both chemical degradation and physical instability, bioequivalence assessment requiring single dose BA/BE studies, multiple dose PK, and food effect studies, and content uniformity across every dosage unit.

The regulatory pathway adds its own complexity. The 505(b)(2) pathway has been relevant for oral biologic development, allowing reference to existing safety and efficacy data while submitting formulation specific studies. In 69.6% of 505(b)(2) NDAs, a scientific bridge was established by a single dose BA/BE study. For truly novel oral biologics like ICOTYDE, full NDA pathways with comprehensive clinical programs remain necessary.

AI and machine learning are the most viable route to compressing this work. Bayesian optimization can identify optimal formulations within 25 experiments, at least 3 fold fewer than classical Design of Experiments and orders of magnitude smaller than full combinatorial screening. AI predictive modeling can screen excipient combinations for compatibility, stability, and release performance before wet lab work begins. Digital twins enable closed loop process optimization with minimal experimental input.

The critical gap: while several ML algorithms exist for small molecule formulations (solid dispersions, cyclodextrin complexes), no equivalent computational tools exist specifically for biologics formulation. The algorithms are built for one world. The market is moving to another.

What This Means for DeepC and Formulation Scientists

The oral biologics revolution creates the exact conditions where AI formulation platforms become necessary.

The formulation spaces are too large for brute force experimentation. With millions of possible combinations of excipients, concentrations, process parameters, and release profiles, traditional trial and error approaches are too slow and too expensive for the pace this market demands. When 400,000 patients adopt a new oral biologic in ten weeks, the commercial pressure to get formulations right on the first attempt is enormous.

DeepC occupies a specific position in this environment: an AI co scientist built for formulation development, the exact phase of drug development where oral biologics succeed or fail.

• Excipient compatibility for peptide systems: DeepC's formulation intelligence, grounded in the FDA Inactive Ingredient Database, FAERS adverse event data, DailyMed, and pharmaceutical literature, can screen excipient combinations for peptide formulations before committing to months of physical stability testing. Permeation enhancer selection, protease inhibitor co formulation, and enteric coating design all require excipient decisions that AI can accelerate.
• Formulation space optimization: AI guided Bayesian optimization through millions of possible combinations, identifying promising formulations in 25 experiments rather than thousands. For oral biologics, where every formulation variable interacts with enzymatic degradation, membrane permeability, and release kinetics simultaneously, computational guidance is not a luxury.
• Bridging the skills gap: The platform encodes accumulated formulation knowledge in accessible models, enabling scientists trained on small molecules to effectively work with oral biologic systems. The knowledge that constrained peptide formulations need specific excipient profiles, or that SNAC based systems require distinct stability considerations from C10 based systems, is embedded in the tools rather than locked in the heads of a handful of specialists.
• Regulatory alignment: Digital documentation of design space exploration and process understanding aligns with Quality by Design principles and regulatory expectations. As oral biologics move through the 505(b)(2) pathway and full NDA submissions, the audit trail from formulation design through clinical manufacturing is a regulatory asset.
• Modified release optimization: Oral biologic formulations are, at their core, modified release tablets requiring enteric coating, targeted drug delivery, and controlled release of both permeation enhancer and active pharmaceutical ingredient. DeepC's tools for release profile optimization apply directly to this challenge.

The $129.77 billion oral drug delivery market is expanding toward $200 billion by 2030. The obesity GLP 1 market alone is projected at $66.57 billion by 2035. The ADC market reaches $32.66 billion on the same timeline. Every molecule in these categories requires formulation science that is becoming more complex, not less. The companies and platforms that master the intersection of peptide science, delivery technology, and computational design will capture the largest share of this growth.